Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

Jounce Therapeutics logo

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Advanced Chart

Key Stats

Today's Range
$1.88
$1.88
50-Day Range
$1.84
$1.94
52-Week Range
$0.58
$5.87
Volume
169,314 shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
See More Headlines

JNCE Stock Analysis - Frequently Asked Questions

Jounce Therapeutics, Inc. (NASDAQ:JNCE) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.15.

Jounce Therapeutics (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/04/2021
Today
6/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JNCE
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.92 million
Pretax Margin
-61.93%

Debt

Sales & Book Value

Annual Sales
$82 million
Price / Cash Flow
N/A
Book Value
$3.54 per share
Price / Book
0.53

Miscellaneous

Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:JNCE) was last updated on 6/2/2025 by MarketBeat.com Staff
From Our Partners